Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Novel use of catalpol in preparation of drug for treating cerebral arterial thrombosis reperfusion injuries

A technology for ischemic stroke and reperfusion injury, applied in the field of medicine, can solve problems such as aggravation

Inactive Publication Date: 2013-01-23
苏州玉森新药开发有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The sequelae of ischemic stroke can accompany the patient's continuous aggravation until death, which brings great pain to the patient and a great economic burden to the family
However, so far, there is no special effective drug treatment for ischemic stroke sequelae. Relatively speaking, traditional Chinese medicine has the advantages of less toxic and side effects, suitable for long-term use, and low cost.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel use of catalpol in preparation of drug for treating cerebral arterial thrombosis reperfusion injuries
  • Novel use of catalpol in preparation of drug for treating cerebral arterial thrombosis reperfusion injuries
  • Novel use of catalpol in preparation of drug for treating cerebral arterial thrombosis reperfusion injuries

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1 Effects on Neurological Impairment Symptoms

[0017] 1.1 Purpose

[0018] Using the rat model of cerebral ischemia-reperfusion injury by thread embolization, observe the effect of catalpol on the nerve defect function of rats with cerebral ischemia-reperfusion injury, so as to determine whether it can promote the recovery of post-ischemic stroke symptoms.

[0019] 1.2 Test material

[0020] 1.2.1 Animals

[0021] Healthy SD male rats, weighing 240-280g.

[0022] 1.2.2 Drugs

[0023] 1.2.2.1 Test drug

[0024] Catalpol, white or colorless powder, weigh 0.3g powder, dissolve to 100ml with deionized water, and administer 1ml / 100g body weight by intragastric administration.

[0025] 1.2.2.2 Positive drugs

[0026] Tianbaoning: Produced by Zhejiang Kangenbei Pharmaceutical Co., Ltd., the clinical daily dosage is 6 tablets. Preparation method: Take 7 tablets, grind them into powder, dissolve them with deionized water to 100ml, and administer 1ml / 100g body wei...

Embodiment 2

[0066] Example 2 Effects on Energy Metabolism Disorders

[0067] 2.1 Purpose

[0068] Using the rat model of cerebral ischemia-reperfusion injury by thread embolization, observe the effect of catalpol on the brain energy metabolism disorder of the cerebral ischemia injury rats, so as to determine whether it has the effect of enhancing brain energy, reducing acidosis, and improving brain energy metabolism disorder effect.

[0069] 2.2 Test material

[0070] 2.2.1 Animals

[0071] Same as 1.2.1.

[0072] 2.2.2 Drugs

[0073] 2.2.2.1 Test drug

[0074] Same as 1.2.2.1.

[0075] 2.2.2.2 Positive drugs

[0076] 2.2.1 Tianbaoning, the same as before.

[0077] 2.2.3 Reagents

[0078] Protein, lactic acid (Lac), pyruvate (Pyru) and ATPase kits were purchased from Nanjing Jiancheng Bioengineering Institute.

[0079] 2.3 Methods and results

[0080] 2.3.1 Preparation of rat cerebral ischemia-reperfusion (MCAO) model

[0081] Same as 1.3.1.

[0082] 2.3.2. Grouping and admin...

Embodiment 3

[0095] Example 3 Effects on Oxidative Stress

[0096] 3.1 Purpose

[0097] A rat model of cerebral ischemia-reperfusion injury was used to observe the effect of catalpol on the oxidative stress of the cerebral cortex of rats with cerebral ischemia injury, so as to determine whether it had the effect of eliminating lipid peroxidation and anti-oxidative stress.

[0098] 3.2 Test material

[0099] 3.2.1 Animals

[0100] Same as 1.2.1.

[0101] 3.2.2 Drugs

[0102] 3.2.2.1 Test drug

[0103] Same as 1.2.2.1.

[0104] 3.2.2.2 Positive drugs

[0105] Butylphthalide, same as 1.2.2.2.

[0106] 3.2.3 Main reagents

[0107] Protein, SOD, MDA kits were purchased from Nanjing Jiancheng Institute of Bioengineering.

[0108] 3.2.4 Main experimental instruments

[0109] HITACHI U-2000 ultraviolet-visible spectrophotometer, produced by Hitachi Instrument Factory, Japan.

[0110] 3.3 Methods and Results

[0111] 3.3.1 Preparation of rat cerebral ischemia-reperfusion (MCAO) model

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel use of catalpol in preparation of a drug for treating cerebral arterial thrombosis reperfusion injuries and belongs to the technical field of medicines. Catalpol can be used for preparation of a drug for treating cerebral arterial thrombosis reperfusion injuries and especially can be used for preparation of a drug for treating cerebral arterial thrombosis reperfusion injuries and neurologic impairment.

Description

technical field [0001] The invention discloses a new application of catalpol, specifically the application of catalpol in the preparation of medicines for treating ischemic stroke-reperfusion injury, and in the preparation of medicines for treating symptoms of neurological deficits in ischemic stroke-reperfusion injuries The application belongs to the field of medical technology. Background technique [0002] Sequelae of ischemic stroke refers to focal symptoms such as hemiplegia, aphasia, and mild disturbance of consciousness left behind after treatment for patients with acute cerebral infarction. Stroke is a common and frequently-occurring disease that endangers human life and health. There are about 15 million stroke patients worldwide every year, of which ischemic stroke accounts for a considerable proportion (75%-85%). However, it is now believed that in the process of ischemic stroke, it is essentially the damage caused by ischemia-reperfusion. The pathophysiological...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P25/28A61P9/10
Inventor 玄振玉黄孝春蔡垠魏惠华陈叶明
Owner 苏州玉森新药开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com